DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo

Johnson & Johnson (NYSE: JNJ)

company name or ticker
Company Photos
(Click to zoom)

IVV, JNJ, MRK, KO: ETF Outflow Alert

Investment Clubs -- Can You Boost Retirement Savings With a Social Network?

Lessons Learned From The Grand Canyon

Dividend Diplomats May Watch List

J&J (JNJ) to File for More than 10 New Products by 2019 - Analyst Blog

UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc. ...

PerkinElmer Hits 52-Week High on Strong Q1, Favorable View - Analyst Blog

Achillion Pharmaceuticals: Should You Buy After The Sell-Off?

Buying The Dips Compared To Dollar Cost Averaging

Johnson & Johnson Just Stepped Up Its Hepatitis C Game

Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C. Should Gilead investors worry?
See More Articles...